HOXA9 and neoplasm: Zhou et al. reported that HOXA9 is identified to be downregulated in cutaneous squamous cell carcinoma (cSCC), and HOXA9 acting as a tumor suppressor impedes the binding of HIF-1α, thus repressing it downstream gene expression [33].